PortalPublikationenPergolide as adjuvant therapy to amisulpride in the treatmen...

Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.

Standard

Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. / Roesch-Ely, D; Göhring, K; Gruschka, P; Kaiser, S; Pfüller, U; Burlon, Marc; Weisbrod, M.

in: PHARMACOPSYCHIATRY, Jahrgang 39, Nr. 3, 3, 2006, S. 115-116.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Roesch-Ely, D, Göhring, K, Gruschka, P, Kaiser, S, Pfüller, U, Burlon, M & Weisbrod, M 2006, 'Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.', PHARMACOPSYCHIATRY, Jg. 39, Nr. 3, 3, S. 115-116. <http://www.ncbi.nlm.nih.gov/pubmed/16721703?dopt=Citation>

APA

Roesch-Ely, D., Göhring, K., Gruschka, P., Kaiser, S., Pfüller, U., Burlon, M., & Weisbrod, M. (2006). Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. PHARMACOPSYCHIATRY, 39(3), 115-116. [3]. http://www.ncbi.nlm.nih.gov/pubmed/16721703?dopt=Citation

Vancouver

Roesch-Ely D, Göhring K, Gruschka P, Kaiser S, Pfüller U, Burlon M et al. Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. PHARMACOPSYCHIATRY. 2006;39(3):115-116. 3.

Bibtex

@article{cb6249c16b1f46d0b609e16a660b026f,
title = "Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.",
abstract = "Negative and cognitive symptoms of schizophrenia are associated with a hypodopaminergic state in the frontal cortex and do not respond to neuroleptics equally well as positive symptoms. Therefore pharmacological strategies, which increase dopamine metabolism in the mesocortical pathways, may prove beneficial to ameliorate these symptoms. We report on a case of a patient with paranoid schizophrenia, who still presented negative and depressive symptoms during treatment with amisulpride for more than 6 weeks. We prescribed pergolide (a mixed D1/D2 agonist) as adjuvant therapy to treat these symptoms. The patient showed an improvement of global psychopathology, decrease of negative and depressive symptoms, while no changes in positive symptoms nor EPS were present. For this patient, the adjuvant therapy of pergolide to amisulpride constituted a valid pharmacological approach to treat negative and depressive symptoms of schizophrenia, without increasing positive symptoms.",
author = "D Roesch-Ely and K G{\"o}hring and P Gruschka and S Kaiser and U Pf{\"u}ller and Marc Burlon and M Weisbrod",
year = "2006",
language = "Deutsch",
volume = "39",
pages = "115--116",
journal = "PHARMACOPSYCHIATRY",
issn = "0176-3679",
publisher = "Georg Thieme Verlag KG",
number = "3",

}

RIS

TY - JOUR

T1 - Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.

AU - Roesch-Ely, D

AU - Göhring, K

AU - Gruschka, P

AU - Kaiser, S

AU - Pfüller, U

AU - Burlon, Marc

AU - Weisbrod, M

PY - 2006

Y1 - 2006

N2 - Negative and cognitive symptoms of schizophrenia are associated with a hypodopaminergic state in the frontal cortex and do not respond to neuroleptics equally well as positive symptoms. Therefore pharmacological strategies, which increase dopamine metabolism in the mesocortical pathways, may prove beneficial to ameliorate these symptoms. We report on a case of a patient with paranoid schizophrenia, who still presented negative and depressive symptoms during treatment with amisulpride for more than 6 weeks. We prescribed pergolide (a mixed D1/D2 agonist) as adjuvant therapy to treat these symptoms. The patient showed an improvement of global psychopathology, decrease of negative and depressive symptoms, while no changes in positive symptoms nor EPS were present. For this patient, the adjuvant therapy of pergolide to amisulpride constituted a valid pharmacological approach to treat negative and depressive symptoms of schizophrenia, without increasing positive symptoms.

AB - Negative and cognitive symptoms of schizophrenia are associated with a hypodopaminergic state in the frontal cortex and do not respond to neuroleptics equally well as positive symptoms. Therefore pharmacological strategies, which increase dopamine metabolism in the mesocortical pathways, may prove beneficial to ameliorate these symptoms. We report on a case of a patient with paranoid schizophrenia, who still presented negative and depressive symptoms during treatment with amisulpride for more than 6 weeks. We prescribed pergolide (a mixed D1/D2 agonist) as adjuvant therapy to treat these symptoms. The patient showed an improvement of global psychopathology, decrease of negative and depressive symptoms, while no changes in positive symptoms nor EPS were present. For this patient, the adjuvant therapy of pergolide to amisulpride constituted a valid pharmacological approach to treat negative and depressive symptoms of schizophrenia, without increasing positive symptoms.

M3 - SCORING: Zeitschriftenaufsatz

VL - 39

SP - 115

EP - 116

JO - PHARMACOPSYCHIATRY

JF - PHARMACOPSYCHIATRY

SN - 0176-3679

IS - 3

M1 - 3

ER -